文献速递前列腺癌

新型生物可吸收低剂量率近距离放疗装置(CivaSheet®)联合根治性前列腺切除术及辅助外照射放疗治疗前列腺癌

Novel bioabsorbable, low-dose rate brachytherapy device (CivaSheet®) with radical prostatectomy and adjuvant external beam radiation for the management of prostate cancer.
PubMed 文献 · BJU Int · 2024-12-09

本研究为单中心、两剂量水平、两阶段初步研究,纳入6例中高危前列腺癌患者,在根治性前列腺切除术中植入CivaSheet,术后对不良病理特征者行辅助外照射放疗。最大测试剂量75 Gy下未见剂量限制性毒性,无术中并发症;6个月时1例生化复发、1例残留病灶并转移,所有患者报告术后勃起功能障碍,1例放疗后尿失禁。结论认为该联合方案可行且安全,短期毒性可耐受,支持进一步前瞻性临床试验评估。

要点

  • 6例中高危前列腺癌患者术中植入CivaSheet联合根治性前列腺切除术,最大测试剂量75 Gy未见剂量限制性毒性。
  • 无术中并发症;6个月时1例生化复发,另1例有残留病灶和转移。
  • 所有患者报告术后勃起功能障碍,1例辅助外照射放疗后出现尿失禁。

核心结论

  • 本研究证明CivaSheet联合根治性前列腺切除术及辅助外照射放疗用于高危前列腺癌具有可行性和安全性,短期毒性可耐受,支持进一步前瞻性临床试验评估。

研究设计与样本

  • 单中心、两剂量水平、两阶段初步研究,纳入中危和高危前列腺癌患者6例,中位(范围)年龄56(53-71)岁。
  • CivaSheet在根治性前列腺切除术中植入,对不良病理特征者术后行辅助外照射放疗,评估毒性和围手术期及术后并发症,并评估外照射放疗后6个月随访时的生化复发。

主要发现

  • 无术中并发症发生;最大测试剂量75 Gy下未观察到剂量限制性毒性。
  • 6个月时1例患者发生生化复发,另1例患者有残留病灶和转移。
  • 所有患者报告术后勃起功能障碍,1例患者在外照射放疗后出现尿失禁。

局限性

  • 本研究为单中心初步经验,样本量小(6例),随访时间短(外照射放疗后6个月),结论支持进一步前瞻性临床试验评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the safety and cancer control of a novel bioabsorbable, low-dose rate brachytherapy device, CivaSheet® (CivaTech Oncology Inc., Durham, NC, USA), in combination with radical prostatectomy (RP) with or without adjuvant external beam radiation therapy (EBRT) for the management of prostate cancer (PCa). PATIENTS AND METHODS: This is an initial, single-centre experience, two-dose level, two-stage study conducted on patients with intermediate- and high-risk PCa. The CivaSheet was implanted during RP, followed by adjuvant EBRT in patients with adverse pathological features. Toxicities and peri- and postoperative complications were assessed. Biochemical recurrence (BCR) at the 6-month follow-up after EBRT was also evaluated. RESULTS: Six patients were enrolled, with a median (range) age of 56 (53-71) years. No intraoperative complications occurred. No dose-limiting toxicities were observed at a maximum tested dose of 75 Gy. BCR occurred in one patient at 6 months, while another patient had residual disease and metastasis at 6 months. All patients reported having postoperative erectile dysfunction and one patient experienced urinary incontinence after EBRT. CONCLUSIONS: This study demonstrated the feasibility and safety of CivaSheet combined with RP and adjuvant EBRT for high-risk PCa. The short-term toxicity profile was well-tolerated, supporting further prospective evaluation with clinical trials.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Okhawere KE, Razdan S, Beksac AT, et al. Novel bioabsorbable, low-dose rate brachytherapy device (CivaSheet®) with radical prostatectomy and adjuvant external beam radiation for the management of prostate cancer. BJU Int. 2024. PMID: 39654390. doi:10.1111/bju.16617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。